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MYCOPHENOLATE MOFETIL MAY PROTECT AGAINST Pneumocystis carinii PNEUMONIA
IN RENAL TRANSPLANTED PATIENTS
Luiz Sergio AZEVEDO, Maria Cristina R. CASTRO, Flavio J. PAULA, Luiz Estevam IANHEZ & Elias DAVID-NETO
SUMMARY
Pneumocystis carinii pneumonia (PCP) is usually prevented in transplanted patients by prophylactic trimethoprim-
sulfamethoxazol (TMS). Mycophenolate mofetil (MMF) has been shown to have a strong protective effect against PCP in rats.
This effect is also suggested in humans by the absence of PCP in patients receiving MMF. After January 1998 MMF has been used
with no TMS prophylaxis in renal transplanted patients. In azathioprine (AZA) treated patients TMS prophylaxis was maintained.
The incidence of PCP was analyzed in both groups. Data were collected in order to have a minimum 6-month follow-up. Two
hundred and seventy-two patients were eligible for analysis. No PCP occurred either in patients under MMF without TMS prophylaxis
nor in patients under AZA. MMF may have an effective protective role against PCP as no patient under MMF, despite not receiving
TMS coverage, developed PCP. A larger, controlled, trial is warranted to consolidate this information.
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INTRODUCTION
Pneumocystis carinii pneumonia (PCP) is a well-known
opportunistic infection in immunosuppressed patients. It may occur
either as sporadic cases or as outbreaks1,6. It may be prevented by the
prophylactic use of trimethoprim-sulfamethoxazole (TMS)2,4.
In 1997, OZ & HUGHES8 showed a strong protective effect of
mycophenolate mofetil (MMF) on experimental PCP in rats with a
null incidence in animals receiving MMF in contrast with other
immunosuppressive drugs (dexamethasone 91%; tacrolimus 90%;
rapamycine 29%). MMF was also able to prevent PCP when
dexamethasone was associated with MMF. These data were in
accordance with those from clinical trials on the use of MMF in
humans3,9,10. The European study3 showed four (2.4%) cases out of 166
patients treated with azathioprine (AZA) and no case in the MMF group.
SOLINGER9 reported 1.2% of PCP in AZA treated patients and no
case in MMF group. A similar result was reported in the Tricontinental
Study10: a 2% of the cases with PCP in patients receiving AZA in
contrast with a null incidence of this disease in patients under MMF.
Therefore, nine (1.8%) out of 492 patients treated with AZA developed
PCP in contrast with a null incidence in 991 MMF treated patients.
The antimicrobial properties of mycophenolic acid have been known
for many decades8. The proposed mechanism of MMF activity against
P. carinii is by inhibiting the enzyme inosine monophosphate
dehydrogenase of the parasite7. MMF impairs lymphocyte proliferation
in humans by the same mechanism.
TMS prophylaxis against PCP is recommended for transplanted
patients under any immunosuppressive drug regimen. However there
is no specific policy regarding such prophylaxis for patients receiving
MMF2. We hypothesized that the use of TMS prophylaxis against PCP
is no more necessary in patients under MMF.
In our transplant unit PCP was a rare complication with sporadic
cases (1% incidence)5 and no specific PCP prophylaxis was used. In
1995 and 1996 there was an increase in the frequency of PCP. At the
end of 1996 and beginning of 1997 there was an epidemic of PCP of
unknown origin: 11 (18%) cases out of 59 patients transplanted during
a 7-month period developed the disease (Fig. 1). PCP occurred from
59th to 156th post-transplant day (average of 90th day).
In March 1997, in order to control the PCP outbreak, we started
using prophylactic TMS (160/800 mg three times a week), starting
immediately after transplantation and maintaining it for six months.
No case of PCP occurred in patients transplanted after the starting of
TMS.
Azathioprine, prednisone and cyclosporin A were solely the drugs
used as immunosuppression until July 1997 when MMF was introduced
in our unit. After January 1998, based on the evidences above mentioned
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we stopped the routine use of TMS in patients receiving MMF, but
continued to prescribe it in patients receiving AZA or any other non-
MMF protocol. There is no specific urinary tract infection prophylaxis
policy in our unit. Therefore TMS was not used for this purpose.
PATIENTS AND METHODS
We reviewed the clinical charts of adults and children, receiving
both living and cadaveric kidneys, transplanted from January 1998 to
June 2002, who received triple therapy consisting of AZA, prednisone
and cyclosporine/tacrolimus or MMF, prednisone and cyclosporine/
tacrolimus. Patients were excluded if they received double transplants
(kidney and pancreas, liver or heart) or if they either died or lost their
kidneys before completing six months, or have their immunosuppressive
drug protocol changed for any reason. Patients who received TMS
therapy for any other reason were also excluded. Data were collected
in January 2003 in order to have a minimum 6-month follow-up. We
analyzed PCP incidence in patients either under AZA or MMF
associated or not with routine prophylactic TMS.
RESULTS
Two hundred and seventy-two patients were eligible for analysis
according to the above criteria: 135 received AZA plus TMS; 11
received AZA without TMS (because of their doctor’s discretion) and
126 patients received MMF with no TMS. No patient under MMF
received TMS.
In none of these three groups of patients a single case of PCP was
observed, in spite of no TMS prophylaxis in patients under MMF.
During this period of observation three new cases of PCP occurred,
but in patients who have been transplanted many years before and not
enrolled in this analysis. None of them was on MMF or received TMS
(Fig. 1).
DISCUSSION
Our study was a retrospective one and not randomized, which limits
conclusions. Nevertheless the analysis of our data suggests that the
prophylactic use of TMS is not necessary when MMF is used. However,
as 11 patients under AZA, in spite of not receiving prophylactic TMS,
did not develop PCP, it is not possible to conclude definitively whether
PCP did not occur in MMF patients due to its own action against the
parasite or it was due to the control of the epidemic outbreak by routine
TMS use. Nevertheless, as the number of patients under AZA with no
TMS was very small in contrast to the large number of patients under
MMF with no TMS and considering data from experiments on rats
and from other clinical trials, it seems logical to attribute the protection
against PCP to an intrinsic effect of MMF. The fact of three patients
under AZA but not enrolled in TMS prophylaxis policy developed PCP
shows that P. carinii infection was not eradicated from our environment.
We concluded: 1- prophylactic TMS effectively controlled the PCP
outbreak. 2- MMF may have an effective protective role against PCP,
as no patient under MMF without TMS prophylaxis developed PCP.
Based on our data and on data from literature the safety of our
policy is likely and suggests that no PCP prophylaxis should be needed
in patients receiving MMF. A larger, controlled, trial is warranted in
order to confirm it.
RESUMO
Micofenolato mofetil pode proteger contra a pneumonia por
Pneumocystis carinii em transplantados renais
A pneumonia por Pneumocystis carinii (PPC) em transplantados
renais é, habitualmente, prevenida pelo uso profilático de trimetoprim-
sulfametoxazol (TMS). Foi demonstrado que o micofenolato mofetil
(MMF) exerce um poderoso efeito protetor sobre a PPC experimental
em ratos. Este efeito também foi sugerido em humanos pela ausência
de PPC em pacientes recebendo MMF. A partir de janeiro de 1998
passamos a usar o MMF em transplantados renais sem profilaxia por
TMS. Nos pacientes recebendo azatioprina (AZA) a profilaxia com
TMS continuou a ser empregada. A incidência de PPC foi analisada
em ambos os grupos. Os dados foram coletados após um mínimo de
seis meses de seguimento. Foram analisados 272 pacientes. Não ocorreu
nenhum caso de PPC tanto nos pacientes recebendo MMF como
naqueles recebendo AZA. O MMF pode ter exercido um efeito protetor
contra a PPC, já que nenhum paciente sob MMF e sem receber
profilaxia por TMS desenvolveu PPC. Estudos maiores e controlados
se fazem necessários para confirmar estas informações.
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